Peptide basics

Melanotan I vs Melanotan II: two names, and the approved medicine that is neither

The two names in this comparison sit close to a third — afamelanotide — which is where the approvals and the trials actually are. Separating those three records is the purpose of this page; it makes no claim about pigmentation, tanning, or any other effect for any of them.

What this comparison measures

This page compares registered studies, phases, regulatory status, publications and readership for two names. It differs from the other comparisons on this site in one respect: on this pair, the naming convention itself distorts the record badly enough that reporting the raw figures without explanation would mislead.¹²³

The naming problem, stated first

For a long time this site recorded Melanotan I with zero registry matches, zero registered studies and no FDA approval. That read as a compound with no human record at all. It was wrong, and the cause was the search term rather than the evidence.¹

The second half of that reading is wrong, and the sources say why. A 2017 dermatology review describes the unregulated, untested synthetic α-MSH analogues commonly known as melanotan I and II, and separately describes afamelanotide as the only α-MSH analogue approved for use in a limited number of medical indications. Three things sit close together in this space: two names sold outside regulation, and one approved product.⁴

Searched under the INN the registry is not empty: 23 studies verified as administering it, including completed phase-3 trials, and an approved product. The collector now uses that term, so this row is directly comparable with every other verified count on the site.³

What afamelanotide's record contains

Afamelanotide is the active ingredient of SCENESSE, approved in the United States under NDA 210797, with approved labelling stating the condition it was approved to treat. The European Medicines Agency maintains a public assessment report for the same product, authorised for prevention of phototoxicity in adults with erythropoietic protoporphyria.⁵⁶

The supporting clinical work includes a randomised trial in erythropoietic protoporphyria published in 2015. That is a narrow indication in a rare disease, and an approval attaches to the product and the condition in its labelling — not to a molecule class, and not to the uses the melanotan names are discussed for.⁷⁵

What Melanotan II's record contains

Melanotan II has one registry match in the snapshot and it verifies: NCT07437560, a placebo-controlled phase-2 study registered in 2026 examining Melanotan II as an adjunct to narrowband ultraviolet-B phototherapy in stable nonsegmental vitiligo. It is listed as recruiting, so it has not reported.²⁹

There is no approved Melanotan II product in the record checked here. The compound appears on FDA's compounding page in the table of nominations withdrawn by their nominators, where the agency's entry notes published case reports describing serious adverse events.⁸

Those case reports are individually citable and worth naming rather than summarising: a 2020 case report and literature review describing renal infarction, and a 2025 case report raising oral mucosal melanoma. Case reports describe single patients and cannot establish that a compound caused what was observed.¹⁰¹¹

Publication trend, 2017 to 2026

A PubMed title/abstract search across 2017 to 2026 returns 49 records for Melanotan II and 7 for Melanotan I. Melanotan II's series peaks at 12 records in 2020 and 2021 and falls to single figures afterwards.¹²¹³

Here too the name is doing the work. Clinical literature about the approved product is indexed under afamelanotide rather than under Melanotan I, so the 7-record figure describes how often the older informal name appears in titles and abstracts — not how much α-MSH research exists.¹³³

Melanotan I is afamelanotide. Searched under that name it holds 23 verified registered trials, a phase-3 ceiling and an approved product — the record was always there, behind the wrong search term.

Melanotan II has one registered phase-2 study, registered in 2026 and not yet reported, and no approved product.

Attention against evidence

Between February and June 2026, the Melanotan II Wikipedia article averaged 11,197 views a month with a peak of 12,706. The afamelanotide article, which this site uses for Melanotan I, averaged 1,781 between February and July 2026 with a peak of 2,542.¹⁴

The page describing an approved medicine with phase-3 trials and an EMA assessment report is read roughly one-sixth as often as the page describing a compound whose only registered study has not reported. Whatever public attention is tracking here, it is not the regulatory or clinical record.¹⁴

Common questions